Fengqi Nie, Yuli Chen, Yanming Hu, Peng Huang, Xuefei Shi, Jingsheng Cai, Mantang Qiu, Enxiu Wang, Kaihua Lu, Ming Sun
Small cell lung cancer (SCLC), recognized as the most aggressive subtype of lung cancer, presents an extremely poor prognosis. Currently, patients with small cell lung cancer face a significant dearth of effective alternative treatment options once they experience recurrence and progression after first-line therapy. Despite the promising efficacy of immunotherapy, particularly immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and various other tumours, its impact on significantly enhancing the prognosis of SCLC patients remains elusive...
March 12, 2024: Immunology